Short answer: 2026 reshuffled the US sunscreen filter toolbox — a modern broad-spectrum filter gained formal US status in August, and two legacy filters came off the monograph in September. If your SPF formula was designed even two years ago, it is worth checking which side of those dates it sits on.
In the United States, sunscreens are not cosmetics — they are over-the-counter drugs governed by an FDA monograph, and only filters on that monograph may be used. This year the monograph moved twice, and both moves land directly on formulation decisions for anyone manufacturing or importing SPF products into the US. Here is what changed and what it means at the factory level.
What changed, in order
| Change | Status | Practical effect |
|---|---|---|
| A modern broad-spectrum UV filter (bemotrizinol, up to 6%) added by final order, effective 9 August 2026 | In force, with a period of exclusivity for the original requester and its licensees | A new, highly photostable option for US formulas — but access is limited during the exclusivity window |
| PABA and trolamine salicylate removed from the monograph, 10 September 2026 | Removed | Any formula still relying on them is no longer monograph-compliant |
| FDA's sunscreen monograph (M020) continues as the rulebook for everything else | Ongoing | US SPF formulas must use only monograph filters, at permitted levels |
The first change matters most strategically. The filter that entered is one European and Asian formulators have used for years — photostable, elegant on skin, broad-spectrum — and its formal US availability signals that the long-frozen US filter list is moving again. The exclusivity period means not every factory can use it immediately; during that window, US-market formulas still build on the established filter set.
The second change is a cleanup, not a surprise: neither legacy filter is widely used in modern formulations. But "not widely used" is not "not used" — old stock formulas, legacy private-label bases and dusted-off 2010s-era files are exactly where these filters resurface. If you inherited a formula, verify its filter list against the current monograph rather than assuming.
Why this matters more for OEM buyers than for formulators
If you buy SPF manufacturing capacity, the monograph is the boundary of what your supplier can legally make for the US market, and it produces three concrete consequences:
- Regional formula forks are the norm, not upselling. A formula legal in the EU or Asia frequently relies on filters that are not on the US monograph — the reason a "global" SPF SKU usually needs a US-specific twin. The filter systems, and therefore the texture and the cost, differ by market. This is chemistry and law, not supplier margin.
- SPF claims are drug claims in the US. The product carries a Drug Facts label, is made under drug establishment registration, and broad-spectrum claims require testing. Any moisturiser or makeup that claims an SPF value pulls itself into this regime — which is why an SPF-tinted product is a different project from a tinted moisturiser, not a variant of one.
- Filter changes invalidate testing. Change the filter system and the SPF value, the broad-spectrum rating and the water-resistance claim all need retesting. Formulation freeze discipline, which governs every cosmetic, is even less negotiable in the drug framework.
Our sunscreen manufacturing guide covers the testing side — ISO methods, SPF validation, water resistance — which is the same discipline that feeds the US drug documentation.
The reformulation math for existing US SKUs
For a brand already selling SPF in the US, 2026 is a paperwork year more than a chemistry year, unless you are one of the few still using the removed filters:
- Audit the filter list of every US SKU against the current monograph. Removals make a formula non-compliant immediately; the fix is a filter swap plus full retest.
- Check the exclusivity status before a brief demands the newly added filter. During the exclusivity window, ask what the equivalent photostable alternative is in your supplier's filter toolbox and what it does to cost and texture.
- Watch the label. Filter changes ripple into the ingredient declaration and the Drug Facts panel; the label is part of the retest package, not an afterthought.
For a new US-market SPF project, the brief should say "US monograph filters only" explicitly — this single line prevents the most common cross-border SPF mistake, which is falling in love with a texture built on non-US filters.
What the changes signal about the next few years
The US filter list has been famously static for decades while the rest of the world moved on. A final order successfully adding a new filter — the first in a generation — suggests more requests in the pipeline, and each addition widens what US-market formulas can do on texture and photostability.
For OEM buyers, the practical stance is to ask prospective suppliers two questions: how do they track monograph orders as they land, and how quickly can they re-fork a formula when the filter toolbox changes? A manufacturer with a documented, stability-tested base formula system and an active regulatory-watching habit absorbs these changes in weeks; one without them will discover the change through a compliance problem.
The same vigilance applies outside the US: filter rules differ in every major market, and our testing and certification guide by market maps the other regimes.
FAQ
Q: What changed in the US sunscreen monograph in 2026? A: Two things. In August, a modern photostable broad-spectrum filter (bemotrizinol, up to 6%) was added by final order, with a period of exclusivity for the original requester and its licensees. In September, PABA and trolamine salicylate were removed from the monograph.
Q: Can I use the newly added filter in my US sunscreen now? A: Only if your supplier's access is not blocked by the exclusivity period that accompanies the order. During that window, most US-market formulas continue on the established monograph filter set; ask your manufacturer what photostable alternatives they can offer and what the retest implications are.
Q: Are PABA and trolamine salicylate banned entirely? A: They are no longer permitted as active filters under the US OTC monograph. Any US SPF formula relying on them must reformulate and retest; modern formulas rarely used them, but legacy bases should be audited.
Q: Why does my European or Asian SPF formula need a different US version? A: US sunscreens are OTC drugs restricted to monograph-listed filters, and many international filter systems are not on that list. The US version needs a US-specific filter system, a Drug Facts label, drug-establishment manufacture and full SPF testing — it is a distinct product, not a translation of the original.